Company research
VYCOR MEDICAL INC
CIK 1424768Updated Sep 26, 2026
SecurityVYCO · OTC · equity
VYCO price & chart
Loading TradingView…
OTC:VYCO on TradingView ↗About the company
With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. (“Vycor”) is a publicly traded company (OTCQB:VYCO) dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and has a growing portfolio of FDA cleared or registered medical solutions that are changing and improving lives every day. The Company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach.
In the news
No coverage from other publishers is available.
Recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
10-K filing
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 830,420Source | 998,117Source | 992,298Source | 860,178Source |
| Property, Plant and Equipment, NetUSD | 133,936Source | 192,693Source | 252,404Source | 303,770Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 86,982Source | 105,648Source | 57,291Source | 37,035Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 218,891Source | 245,260Source | 215,231Source | 156,204Source |
| Inventory, NetUSD | 159,202Source | 222,189Source | 234,145Source | 248,874Source |
| Assets, CurrentUSD | 563,422Source | 695,719Source | 584,090Source | 517,763Source |
| Prepaid Expense and Other Assets, CurrentUSD | 97,230Source | 121,705Source | 76,684Source | 74,438Source |
| Operating Lease, Right-of-Use AssetUSD | 55,283Source | 103,705Source | 149,804Source | 32,645Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 4,917,299Source | 4,688,200Source | 4,317,774Source | 3,801,049Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | — | — | 27Source |
| Common Stock, Value, IssuedUSD | 3,347Source | 3,347Source | 3,273Source | 3,263Source |
| Additional Paid in CapitalUSD | 29,431,959Source | 29,431,959Source | 29,365,070Source | 29,355,626Source |
| Retained Earnings (Accumulated Deficit)USD | -33,648,856Source | -33,252,060Source | -32,820,490Source | -32,426,429Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 127,677Source | 127,677Source | 127,677Source | 127,675Source |
| Stockholders' Equity Attributable to ParentUSD | -4,086,879Source | -3,690,083Source | -3,325,476Source | -2,940,871Source |
| Liabilities and EquityUSD | 830,420Source | 998,117Source | 992,298Source | 860,178Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 4,781,468Source | 4,496,543Source | 4,074,487Source | 3,654,796Source |
| Operating Lease, Liability, CurrentUSD | 52,221Source | 48,158Source | 45,321Source | 29,591Source |
| Accounts Payable, CurrentUSD | 84,755Source | 147,569Source | 117,801Source | 200,044Source |
| Operating Lease, Liability, NoncurrentUSD | — | 52,221Source | 100,379Source | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 89,938Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 48,838Source | 26,783Source | 10,141Source | 185,610Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -23,678Source | 33,404Source | 59,027Source | 30,108Source |
| Increase (Decrease) in InventoriesUSD | 8,792Source | -11,956Source | -14,729Source | 56,868Source |
| Increase (Decrease) in Accounts PayableUSD | -62,813Source | 29,768Source | -82,243Source | -27,676Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -13,471Source | 60,110Source | 29,430Source | -217,016Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -4,383Source | -4,199Source | -9,386Source | -2,780Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 5,224Source | 4,199Source | 9,386Source | 2,780Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -812Source | -7,554Source | 211Source | 165,889Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -18,666Source | 48,357Source | 20,256Source | -53,906Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 21,196Source | 40,504Source | 5,550Source | 8,246Source |
| Income Taxes Paid, NetUSD | — | — | 0Source | 0Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | 2,364Source | — | — |
| DepreciationUSD | 63,143Source | 63,910Source | 60,752Source | 61,403Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -508Source | -230Source | -206Source | -964Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | -70,190Source | -106,951Source | -63,080Source | -399,705Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | -2,236Source | -249Source | -6,611Source | -5,212Source |
| Inventory Write-downUSD | — | 17,211Source | — | 15,515Source |
| Net Income (Loss) Attributable to ParentUSD | -72,426Source | -107,200Source | -69,691Source | -404,917Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -396,796Source | -431,570Source | -394,061Source | -729,287Source |
| Nonoperating Income (Expense)USD | -104,090Source | -97,806Source | -103,271Source | -93,191Source |
| Operating ExpensesUSD | 1,527,207Source | 1,431,660Source | 1,275,463Source | 1,388,859Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 1,863,400Source | 1,589,324Source | 1,460,604Source | 1,222,989Source |
| Cost of RevenueUSD | 302,293Source | 166,809Source | 144,950Source | 140,644Source |
| Selling, General and Administrative ExpenseUSD | 1,457,723Source | 1,356,814Source | 1,195,408Source | 1,330,627Source |
| Operating Income (Loss)USD | 33,900Source | -9,145Source | 40,191Source | -306,514Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -70,190Source | -106,951Source | -63,080Source | -399,705Source |
| Net Income (Loss) Attributable to ParentUSD | -72,426Source | -107,200Source | -69,691Source | -404,917Source |
| Earnings Per Share, BasicUSD per share | -0.01Source | -0.01Source | -0.01Source | -0.02Source |
| Earnings Per Share, DilutedUSD per share | -0.01Source | -0.01Source | -0.01Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 33,372,796Source | 32,884,882Source | 32,603,767Source | 31,708,076Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 33,372,796Source | 32,884,882Source | 32,603,767Source | — |
| Additional Financial Items | ||||
| Depreciation, Depletion and Amortization, NonproductionUSD | 59,521Source | 59,521Source | 57,497Source | 58,232Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -508Source | -230Source | -206Source | -964Source |
| Gross ProfitUSD | 1,561,107Source | 1,422,515Source | 1,315,654Source | 1,082,345Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -44,630Source | -81,834Source | -42,829Source | -382,553Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | -70,190Source | -106,951Source | -63,080Source | -399,705Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | -0.01Source | -0.01Source | 0Source | -0.01Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | -0.01Source | -0.01Source | 0Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | -2,236Source | -249Source | -6,611Source | -5,212Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -396,796Source | -431,570Source | -394,061Source | -729,287Source |
| Nonoperating Income (Expense)USD | -104,090Source | -97,806Source | -103,271Source | -93,191Source |
| Operating ExpensesUSD | 1,527,207Source | 1,431,660Source | 1,275,463Source | 1,388,859Source |
| Preferred Stock Dividends and Other AdjustmentsUSD | 2,919,330Source | 2,594,960Source | 2,270,590Source | 1,946,220Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | 324,370Source | 324,370Source | 324,370Source | 324,370Source |
| Research and Development ExpenseUSD | 9,963Source | 15,325Source | 22,558Source | — |
Filing attachments
ex99-1.htm · 8-K · 2026-08-14
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Vycor Medical Releases Financial Results for the Three And Six Months Ended June 30, 2026 BOCA RATON, FL (August 14, 2026) - Vycor Medical, Inc. (“Vycor”) (OTCQB - VYCO), today announced financial results for the three and six months ended June 30, 2026. The Company operates through two business units: Vycor Medical, which produces the ViewSite™ Brain Access System (VBAS) for neurosurgeons; and NovaVision ®, a business in development which offers …
Read attachment ↗ex99-1.htm · 8-K · 2026-05-15
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Vycor Medical Releases Financial Results for the Three Months Ended March 31, 2026 BOCA RATON, FL (May 15, 2026) - Vycor Medical, Inc. (“Vycor”) (OTCQB - VYCO), today announced financial results for the three months ended March 31, 2026. The Company operates through two business units: Vycor Medical, which produces the ViewSite™ Brain Access System (VBAS) for neurosurgeons; and NovaVision ®, a business in development which offers therapy programs …
Read attachment ↗ex99-1.htm · 8-K · 2026-03-31
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Vycor Medical Releases Financial Results for the for the Year Ended December 31, 2025 BOCA RATON, FL (March 31, 2026) - Vycor Medical, Inc. (“Vycor” or the “Company”) (OTCQB - VYCO), today announced financial results for the year ended December 31, 2025. The Company operates through two business units: Vycor Medical, which produces the ViewSite™ Brain Access System (VBAS) for neurosurgery; and NovaVision ®, a business in development which offers t…
Read attachment ↗ex99-1.htm · 8-K · 2025-11-14
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Vycor Medical Releases Financial Results for the Three and Nine Months Ended September 30, 2025 BOCA RATON, FL (November 14, 2025) - Vycor Medical, Inc. (“Vycor” or the “Company”) (OTCQB - VYCO), today announced financial results for the three and nine months ended September 30, 2025. The Company operates through two business units: Vycor Medical, which produces the ViewSite™ Brain Access System (VBAS) for neurosurgery; and NovaVision ®, a busines…
Read attachment ↗ex99-1.htm · 8-K · 2025-08-08
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Vycor Medical Releases Financial Results for the Three and Six Months Ended June 30, 2025 BOCA RATON, FL (August 8, 2025) - Vycor Medical, Inc. (“Vycor” or the “Company”) (OTCQB - VYCO), today announced financial results for the three and six months ended June 30, 2025. The Company operates through two business units: Vycor Medical, which produces the ViewSite™ Brain Access System (VBAS) for neurosurgery; and NovaVision ®, a business in developmen…
Read attachment ↗ex99-1.htm · 8-K · 2025-05-15
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Vycor Medical Releases Financial Results for the Three Months Ended March 31, 2025 BOCA RATON, FL (May 15, 2025) - Vycor Medical, Inc. (“Vycor” or the “Company”) (OTCQB - VYCO), today announced financial results for the three months ended March 31, 2025. The company operates through two business units: Vycor Medical, which produces the ViewSite™ Brain Access System (VBAS) for neurosurgery; and NovaVision®, a business in development which offers th…
Read attachment ↗